Beyond the lungs: How COVID-19 affects the rest of the body

Thursday, July 30, 2020

COVID-19 can have a negative impact on systems throughout the body, beyond just the lungs, according to a review published in Nature Medicine. Two authors of the review joined host David H. Henry, MD, to discuss their article, “Extrapulmonary manifestations of COVID-19.”

Aakriti Gupta, MD, of Columbia University Irving Medical Center, and Kartik Sehgal, MD, of Dana Farber Cancer Institute, discussed:

  • ACE2, the entry receptor for SARS-CoV-2
  • Neurologic and gastrointestinal manifestations of COVID-19
  • Mechanisms of coagulation and thromboprophylaxis
  • COVID-19 in cancer patients
  • The impact of quarantine on cardiology patients
  • The lasting effects of COVID-19 and the need for follow-up
  • The importance of international collaboration for clinical trials.

For more details on how COVID-19 can affect the body, see the full review in Nature Medicine:

Gupta A. et al. Nat Med. 2020 Jul;26(7):1017-1032.

Disclosures:

Dr. Henry and Dr. Sehgal have no financial disclosures relevant to this episode.

Dr. Gupta disclosed relationships with the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, the Ben C. Martin Law Firm for work related to the Cook inferior vena cava filter litigation, Edward Lifesciences, and Heartbeat Health.

* * *

For more MDedge Podcasts, go to mdedge.com/podcasts

Email the show: [email protected]

Interact with us on Twitter: @MDedgehemonc

David Henry on Twitter: @davidhenrymd

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.